SCHEMBL3638893

SCHEMBL3638893

CNC(=O)c1cccc(-c2ccc3cc(C(=O)O)[nH]c3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.49
▸ CDK8 P49336 1/20 0.48
▸ CRBN Q96SW2 1/20 0.47
▸ EIF4A3 P38919 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ DAO P14920 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ SRD5A2 P31213 1/20 0.47
▸ HDAC8 Q9BY41 2/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ PIK3CG P48736 1/20 0.42
▸ NR4A2 P43354 1/20 0.42
▸ PDK2 Q15119 1/20 0.42
▸ RHEB Q15382 1/20 0.42
▸ CYP17A1 P05093 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4137392 0.90 CDK8 (0.51) CDK8CRBNKDM4EHSD17B10MAPT
SCHEMBL3642463 0.88 ALOX15 (0.52) ALOX15CRBNEIF4A3KDM4EHSD17B10
SCHEMBL3644122 0.83 KDM4E (0.50) CDK8EIF4A3KDM4EHSD17B10MAPT
SCHEMBL3389181 0.80 HSD17B10 (0.66) EIF4A3KDM4EHSD17B10MAPTDAO
SCHEMBL3643396 0.78 SMAD3 (0.55) EIF4A3KDM4EHSD17B10MAPTDAO
SCHEMBL3640951 0.77 PIN1 (0.54) CRBNKDM4EHSD17B10MAPTDAO
SCHEMBL15131404 0.77 RXRA (0.48) EIF4A3KDM4EHSD17B10MAPTDAO
SCHEMBL19928419 0.77 EIF4A3 (0.47) EIF4A3KDM4EHSD17B10MAPTDAO
SCHEMBL13702375 0.77 HDAC8 (0.68) CDK8CRBNHDAC8HDAC6PIK3CG
SCHEMBL6515240 0.76 PIN1 (0.59) ALOX15EIF4A3KDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US claimed
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 — — EP disclosed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US disclosed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 ALOX15 32/4885CDK8 2275/4885CRBN 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback